Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jörge E. Cortes(Augusta University Health), Dan Jones(The Ohio State University Wexner Medical Center), Megan Breeden(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Francis J. Giles(National University of Ireland), William G. Wierda(University of Maryland, Baltimore), Susan O’Brien(University of California, Irvine), Jianqin Shan(The University of Texas MD Anderson Cancer Center), Nubia Reeves(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(Chinese Academy of Agricultural Sciences)
Cited by 298
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k